Skip to main content

Table 1 The most important clinical characteristics of patients with CR/MDR-PA infection or colonization

From: Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals

 

All (n = 92)

Infection (n = 68)

Colonization (n = 24)

OR (95% CI)

Demographic characteristics

 Male sex (%)

56 (61)

44 (65)

12 (52)

1.8 (0.7–4.7)

 Age: median; years (IQR)

68 (52–74)

69 (51–74)

66 (52–75)

 

 Patients ≥65 years (%)

52 (57)

37 (54)

15 (63)

0.7 (0.3–1.9)

Previous contact with health care system

 Hospitalization within 90 days (%)

35 (38)

25 (37)

10 (42)

0.8 (0.3–2.1)

 Long-term healthcare facilities stay within 90 days (%)

5 (5)

4 (6)

1 (4)

1.4 (0.2–13.5)

 Antibiotic therapy in previous 90 days (%)

82 (89)

60 (88)

22 (92)

0.7 (0.1–3.5)

 Surgery in previous 30 days (%)

53 (58)

38 (56)

15 (63)

0.8 (0.3–2.0)

 Intensive care unit stay; duration in days: median (IQR)

57 (62); 15 (8–24.5)

40 (59)

17 (71)

0.6 (0.2–1.6)

Invasive procedures in previous 30 days

 Bronchoscopy

30 (33)

25 (37)

5 (21)

2.2 (0.7–6.7)

 Hemodialysis

17 (19)

13 (19)

4 (17)

1.2 (0.3–4.1)

 Endoscopy

17 (18)

14 (21)

3 (13)

1.8 (0.5–7.0)

 Other

16 (17)

10 (15)

6 (25)

0.5 (0.2–1.6)

Invasive device use on the microorganism isolation day

 Mechanical ventilation of the lungs

47 (51)

34 (50)

13 (54)

0.8 (0.3–2.2)

 Central venous catheter

48 (52)

33 (49)

15 (63)

0.6 (0.2–1.5)

 Urinary catheter

51 (55)

38 (56)

13 (54)

1.1 (0.4–2.7)

 Epicystostomy

9 (10)

7 (10)

2 (8)

1.3 (0.2–6.5)

Co-morbidities

 Congestive cardiac insufficiency

29 (32)

21 (31)

8 (33)

0.9 (0.3–2.4)

 Chronic renal failure

21 (23)

16 (24)

5 (21)

1.2 (0.4–3.6)

 Diabetes mellitus

20 (22)

15 (22)

5 (21)

1.1 (0.3–3.4)

 Chronic pulmonary disease

17 (18)

12 (18)

5 (21)

0.8 (0.3–2.6)

 Malignant tumor

16 (16)

9 (13)

7 (25)

0.4 (0.1–1.1)

 Hemiplegia

14 (16)

11 (16)

3 (13)

1.4 (0.3–5.3)

 Myocardial infarct

13 (14)

9 (13)

4 (17)

0.8 (0.2–2.8)

 Cerebrovascular disease

12 (13)

11 (16)

1 (4)

4.4 (0.5–36.4)

 Othera

34 (37)

27 (40)

7 (29)

1.6 (0.6–4.4)

  1. aHIV, AIDS, hematologic malignancy, dementia, connective tissue disease, liver disease, peripheral vascular disease, ulcer disease, neutropenia, trauma, burn